
Sign up to save your podcasts
Or


At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate.
In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.
To learn more about the topic in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4
1111 ratings
At the recent World Conference on Lung Cancer and European Society for Medical Oncology annual meetings, two packages of lung cancer data from a partnership between Akeso and Summit Therapeutics and another collaboration between iTeos Therapeutics and GSK showed much promise of disrupting the current standard of care. But they also drew some questions and debate.
In this week's episode of “The Top Line,” Angus Liu from Fierce Pharma and Gabrielle Masson from Fierce Biotech discuss the key issues behind those two readouts.
To learn more about the topic in this episode:
See omnystudio.com/listener for privacy information.

30,653 Listeners

3,218 Listeners

976 Listeners

1,896 Listeners

1,637 Listeners

1,093 Listeners

325 Listeners

1,037 Listeners

228 Listeners

6,083 Listeners

34 Listeners

145 Listeners

19 Listeners

77 Listeners

145 Listeners